Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aptevo Therapeutics ( (APVO) ) just unveiled an announcement.
On September 16, 2025, Aptevo Therapeutics announced a 100% remission rate in Cohort 3 of its Phase 1b/2 RAINIER trial for mipletamig in combination with venetoclax and azacitidine for newly diagnosed AML patients unfit for intensive chemotherapy. The trial showed no dose-limiting toxicities, highlighting mipletamig’s strong safety profile and potential to redefine frontline AML treatment, positioning Aptevo to capture a significant share of the multibillion-dollar AML market.
The most recent analyst rating on (APVO) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Aptevo Therapeutics stock, see the APVO Stock Forecast page.
Spark’s Take on APVO Stock
According to Spark, TipRanks’ AI Analyst, APVO is a Underperform.
Aptevo Therapeutics’ stock score is significantly impacted by its challenging financial performance, marked by declining revenues, high leverage, and negative cash flows. The technical analysis indicates bearish momentum, while the valuation is weakened by persistent losses. However, promising developments in its oncology pipeline offer potential upside if successfully executed.
To see Spark’s full report on APVO stock, click here.
More about Aptevo Therapeutics
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for cancer treatment. The company is currently evaluating mipletamig, a CD123 x CD3 bispecific antibody, in combination with standard care for acute myeloid leukemia (AML) and has another candidate, ALG.APV-527, for multiple solid tumors.
Average Trading Volume: 2,268,370
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.73M
For an in-depth examination of APVO stock, go to TipRanks’ Overview page.